Antidotes for factor Xa inhibitors and methods of using the same
View Patent ↗The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO. 21 or an amino acid sequence having at least 95% sequence identity to SEQ ID NO. 21, wherein the polypeptide has (a) reduced procoagulant activity compared to wild-type factor Xa, (b) is capable of binding to a factor Xa inhibitor, (c) does not assemble into a prothrombinase complex and (d) prevents cleavage of amino acid residues 347-365 from the polypeptide.
2. The polypeptide of claim 1 , wherein the amino acid sequence that has at least 95% sequence identity to SEQ ID NO. 21 comprises a substitution, as compared to SEQ ID NO: 3, at the amino acid residue corresponding to Arg429 of SEQ ID NO: 3.
3. The polypeptide of claim 2 , wherein the substitution is Arg 429Gln.
4. The polypeptide of claim 2 , wherein the amino acid sequence that has at least 95% sequence identity to SEQ ID NO. 21 comprises a substitution, as compared to SEQ ID NO: 3, at the amino acid residue corresponding to Thr443 of SEQ ID NO: 3.
5. The polypeptide of claim 4 , wherein the substitution is Thr443Ala.
6. The polypeptide of claim 1 , wherein the amino acid sequence that has at least 95% sequence identity to SEQ ID NO. 21 comprises a substitution, as compared to SEQ ID NO: 3, at the amino acid residue corresponding to Ser436 of SEQ ID NO: 3.
7. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO. 21.
8. An isolated polypeptide consisting essentially of the amino acid sequence of SEQ ID NO. 21.
9. An isolated two-chain polypeptide prepared from the polypeptide of claim 2 or 3 through cleavage at a linker located at amino acid residues 106-111.
10. A peptide conjugate comprising a carrier covalently or non-covalently linked to a polypeptide of claim 1 or 7 .
11. The peptide conjugate of claim 10 , wherein the carrier is a liposome, a micelle, a pharmaceutically acceptable polymer, or a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising a carrier and a polypeptide of claim 1 or 7 .
13. A polynucleotide encoding for a polypeptide of claim 1 or 7 .
14. A method for preparing a polypeptide of claim 1 or 7 comprising expressing a polynucleotide encoding the polypeptide in a prokaryotic or eukaryotic host cell.
15. The method of claim 14 , further comprising isolating the polypeptide.
16. An isolated prokaryotic or eukaryotic host cell comprising a polynucleotide encoding the polypeptide of claim 1 or 7 .
17. A composition comprising a carrier and a prokaryotic or eukaryotic host cell of claim 16 .
18. A method of neutralizing or reversing anticoagulation in a subject undergoing anticoagulant therapy with a factor Xa inhibitor in need of cessation of anticoagulation or suffering from bleeding, comprising administering to the subject an effective amount of a composition of claim 12 .
19. The method of claim 18 , wherein the factor Xa inhibitor is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitor, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, PD-348292, otamixaban, edoxaban, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof.
20. The method of claim 18 , wherein the subject is experiencing a clinical major bleeding event selected from the group consisting of hemorrhage, bleeding into vital organs, bleeding requiring re-operation or a new therapeutic procedure, and a bleeding index of equal to or more than 2.0 with an associated overt bleeding.
21. The method of claim 18 , wherein the composition is administered prior to a surgery.
22. A method for selectively binding and inhibiting an exogenously administered factor Xa inhibitor in a subject, comprising administering to the subject an effective amount of a composition of claim 12 .
23. The method of claim 22 , wherein the factor Xa inhibitor is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitor, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, PD-348292, otamixaban, edoxaban, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof.
24. The method of claim 22 , wherein the subject is experiencing a clinical major bleeding event selected from the group consisting of hemorrhage, bleeding into vital organs, bleeding requiring re-operation or a new therapeutic procedure, and a bleeding index of equal to or more than 2.0 with an associated overt bleeding.
25. The method of claim 24 , wherein the composition is administered prior to a surgery.